Purine phosphodiesterase 7 (PDE 7) inhibitors of the following formulas wherein R1, Z, Y and J are described herein, and analogs thereof are provided which are useful in treated T-cell mediated diseases. R2 is defined by the following (a) heteroaryl, or heterocyclo, either of which may be optionally substituted with one to three groups T1, T2, T3; (b) aryl substituted with one to three groups T1, T2, T3 provided that at least one of T1, T2, T3 is other than H; or (c) aryl fused to a heteroaryl or heterocyclo ring wherein the combined ring system may be optionally substituted with one to three groups T1, T2, T3.